Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 2948-2958

  Sutton, Angela ^a,b   Friand, Veronique ^a   Papy Garcia, Dulce ^c   Dagouassat, Maylis ^a   Martin, Loïc ^d   Vassy, Roger ^a   Haddad, Oualid ^a   Sainte Catherine, Odile ^a   Kraemer, Michel ^a   Saffar, Line ^a   Perret, Gerard Yves ^a   Courty, Jose ^c   Gattegno, Liliane ^a,b   Charnaux, Nathalie ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA XYLOSIDE; CARBOHYDRATE DERIVATIVE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTIBODY; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; ENZYME ANTIBODY; FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR; GELATINASE B; GELATINASE B ANTIBODY; GLYCOSAMINOGLYCAN; LOW MOLECULAR WEIGHT HEPARIN; OTR 4120; OTR 4131; RANTES; RECEPTOR ANTIBODY; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BIOMIMETICS; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE;

BIOMIMETIC MATERIALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL5; CHEMOTAXIS; GLYCOSAMINOGLYCANS; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS;

EID: 36749013634     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0114     Document Type: Article

References (46)

1. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7.
2. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
3. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15.
4. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-61.
5. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001;40:6303-18.
6. Proudfoot AEI, Fritchley S, Borlat F, et al. The BXBB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001;276:10620-6.
7. Yip GW, Smollich M, Götte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006;5:2139-48.
8. Slimani H, Charnaux N, Mbemba E, et al. Binding of the CC-chemokine RANTES to syndecan-1 and -4 expressed on HeLa cells. Glycobiology 2003;13:623-34.
9. Slimani H, Charnaux N, Mbemba E, et al. Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochem Biophys Acta 2003;1617:80-8.
10. Johnson Z, Kosco-Vilbois MH, Herrenn S, et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 2004;173:5776-85.
11. Kuschert GS, Coulin F, Power CA, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-68.
12. Marotta F, Vangieri B, Cecere A, Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter 2004;155:187-99.
13. Marra F, Romanelli RG, Giannini C, et al. Monocyte chemotactic protein-1 as a chemoattractant for human stellate cells. Hepatology 1999;29:140-8.
14. Maltby J, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates: associations between GROα and histopathological evidence of alcoholic hepatitis. Hepatology 1996;24:1156-60.
15. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastroenterol Liver Physiol 2003;285:G949-58.
16. Sutton A, Friand V, Brule-Donneger S, et al. Stromal cell-derived factor-1/CXCL12 stimulates human hepatoma cell growth, migration and invasion. Mol Cancer Res 2007;5:21-33.
17. Lu P, Nakamoto Y, Nemoto-Sasaki Y, et al. Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. Am J Pathol 2003;162:1249-58.
18. Yang X, Lu P, Fujii C, et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer 2006;118:1869-76.
19. Barbosa I, Morin C, Garcia S, et al. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J Cell Sci 2005;118:253-64.
20. Rouet V, Meddahi-Pelle A, Miao HQ, Vlodavsky I, Caruelle JP, Barritault D. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J Biomed Mater Res A 2006;78:792-7.
21. Papy-Garcia D, Barbier-Chassefiere V, Rouet V, et al. Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005;38:4647-54.
22. Sutton A, Imbert A, Igoudjil A, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005;15:311-9.
23. Lucas M, Mazzone T. Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. J Biol Chem 1996;271:13454-60.
24. Vita C, Drakopoulou E, Ylisastigui L, et al. Synthesis and characterization of biologically functional biotinylated RANTES. J Immunol Methods 2002;266:53-65.
25. Charnaux N, Brule S, Hamon M, et al. Syndecan-4 is a signaling molecule for stromal cell-derived factor-1 (SDF-1)/CXCL12. FEBS J 2005;272:1937-51.
26. Brule S, Charnaux N, Sutton A, et al. The shedding of syndecan-4 and syndecan-1 from Hela cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006;16:488-501.
27. Ashikari S, Habuchi H, Kimata K. Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor. J Biol Chem 1995;270:29586-93.
28. Derksen PWB, Keehnen RMJ, Evers LM, van Oers MHJ, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002;99:1405-10.
29. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000;19:5606-13.
30. Aamiri A, Mobarek A, Carpentier G, Barritault D, Gautron J. Effects of substituted dextran on reinnervation of a skeletal muscle in adult rats during regeneration. C R Acad Sci III 1995;318:1037-43.
31. Chang TL, Gordon CJ, Roscic-Mrkic B, et al. Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signalling pathway and enhances human immunodeficiency virus type 1 infectivity. J Virol 2002;76:2245-54.
32. Arii S, Mise M, Harada T, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996;24:316-22.
33. Sakamoto Y, Mafune K, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 2000;17:237-43.
34. Locati M, Deuschle U, Massardi ML, et al. Analysis of the gene expression profile activated by the CC-chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol 2002;168:3557-62.
35. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002;62:1093-102.
36. Proudfoot AEI, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 2003;100:1885-90.
37. Roscic-Mrkic B, Fischer M, Leemann C, et al. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003;102:1169-77.
38. Meddahi A, Caruelle JP, Gold L, Rosso Y, Barritault D. New concepts in tissue repair: skin as an example. Diabetes Metab 1996;22:274-8.
39. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparin-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
40. Meddahi A, Alexakis C, Papy D, Caruelle JP, Barritault D. Heparin-like polymer improved healing of gastric and colic ulceration. J Biomed Mater Res 2002;60:497-501.
41. Alexakis C, Mestries P, Garcia S, et al. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-β1. FASEB J 2004;18:1147-9.
42. Bittoun P, Bagheri-Yarmand R, Chaubet F, Crepin M, Jozefonvicz J, Fermandjian S. Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor binding studies. Biochem Pharmacol 1999;57:1399-406.
43. Hamma-Kourbali Y, Vassy R, Starzec A, et al. Vascular endothelial growth factor 165 (VEGF165) activities are inhibited by carboxymethylbenzylamide dextran that competes for heparin binding to VEGF165 and VEGF165-KDR complexes. J Biol Chem 2001;276:39748-54.
44. Shaw JP, Johnson Z, Borlat F, et al. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure 2004;12:2081-3.
45. Bass MD, Roach KA, Morgan MR, et al. Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix. J Cell Biol 2007;177:527-38.
46. Lin F, Ren XD, Doris G, Clark RA. Three-dimensional migration of human adult dermal fibroblasts from collagen lattices into fibrin/fibronectin gels requires syndecan-4 proteoglycan. J Invest Dermatol 2005;124:906-13.